Stephen Thompson

Stephen Thompson is a Managing Director and Founding Partner at Brandon Capital Partners, based in Sydney, New South Wales, Australia. He holds a PhD in Immunology from Kings College London and an MBA from Imperial College London, having initially spent ten years working as a research immunologist across laboratories in London and California. Transitioning into venture capital and product development, Thompson served as a Director at Apax Partners in London before relocating to Australia to establish his current firm. He currently holds active director positions at several biotechnology startups, including OncoRes Medical and George Medicines, and previously guided portfolio companies to successful exits, such as the 2018 acquisition of Elastagen by Allergan. Thompson focuses his investment strategy on the broader life sciences sector, leveraging his extensive scientific background to scale early-stage medical device and immunology ventures.